HIV-Associated Lipodystrophy in the Modern ART Era

HIV-associated lipodystrophy continues to be a health concern for people living with HIV (PWH) within the modern antiretroviral therapy (ART) era. While the prevalence of the condition has decreased significantly compared to earlier periods of treatment, it remains a factor in cardiometabolic health and long-term patient care.

A study highlighted by TheBodyPro in April 2026 indicates that the prevalence of lipodystrophy among people living with HIV is currently 2.5%. This figure is considered objectively low when compared to estimates from the pre-modern ART era, which ranged from 20% to 70%.

Clinical Definition and Presentation

Lipodystrophy syndrome is defined as a medical condition characterized by the absence of adipose tissue in the absence of underlying starvation or macromolecule breakdown. In patients with HIV/AIDS, the use of highly active antiretroviral therapy (HAART) can lead to this condition.

Clinically, the syndrome is recognized by a specific phenotype that emerged in the mid-1990s. This presentation includes the loss of fat in the limbs, facial wasting, and the accumulation of fat in the abdominal region.

Cardiometabolic Risks and Visceral Fat

The accumulation of visceral abdominal fat is a primary hallmark of what is described as metabolically unhealthy obesity. This complex syndrome involves fat deposition not only in the viscera but often in the liver, heart, and skeletal muscle.

According to information released by the European AIDS Treatment Group on August 26, 2025, this specific type of obesity is associated with several serious cardiometabolic conditions, including:

• Hyperglycemia and insulin resistance
• Dyslipidemias
• Elevated risk for diabetes
• Coronary artery disease and cardiovascular events
• Accelerated frailty

The distinction between metabolically healthy obesity and its unhealthy counterpart is largely driven by where the fat is stored in the body, with visceral storage posing the highest risk to the patient.

Correlation with Antiretroviral Therapy

The development of lipodystrophy has been linked to the types of medications used to treat HIV. In the early combination ART era, clinicians recognized that the incorporation of first-generation protease inhibitors and thymidine analogs into regimens contributed to the lipodystrophy phenotype and its subsequent metabolic consequences.

Research indicates that lipodystrophy remains correlated with the duration of exposure to some newer antiretroviral drugs, suggesting that while modern regimens have reduced the overall prevalence, the risk persists depending on the length of treatment.

Despite the lower prevalence rates observed in 2026, reports from the VAMOS study emphasize that lipodystrophy remains a concern for those taking modern ART regimens due to the associated risks of cardiovascular and metabolic disease.